These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25817387)

  • 41. Exploration of a new type of antimalarial compounds based on febrifugine.
    Kikuchi H; Yamamoto K; Horoiwa S; Hirai S; Kasahara R; Hariguchi N; Matsumoto M; Oshima Y
    J Med Chem; 2006 Jul; 49(15):4698-706. PubMed ID: 16854076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual targeting of aminoacyl-tRNA synthetases to the apicoplast and cytosol in Plasmodium falciparum.
    Jackson KE; Pham JS; Kwek M; De Silva NS; Allen SM; Goodman CD; McFadden GI; Ribas de Pouplana L; Ralph SA
    Int J Parasitol; 2012 Feb; 42(2):177-86. PubMed ID: 22222968
    [TBL] [Abstract][Full Text] [Related]  

  • 43. One-pot, multicomponent synthesis of 2,3-disubstituted quinazolin-ones with potent and selective activity against Toxoplasma gondii.
    Brown CE; Kong T; Bordón C; Yolken R; Jones-Brando L; McNulty J
    Bioorg Med Chem Lett; 2018 May; 28(9):1642-1646. PubMed ID: 29598911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A genomic and evolutionary approach reveals non-genetic drug resistance in malaria.
    Herman JD; Rice DP; Ribacke U; Silterra J; Deik AA; Moss EL; Broadbent KM; Neafsey DE; Desai MM; Clish CB; Mazitschek R; Wirth DF
    Genome Biol; 2014; 15(11):511. PubMed ID: 25395010
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structural analysis of malaria-parasite lysyl-tRNA synthetase provides a platform for drug development.
    Khan S; Garg A; Camacho N; Van Rooyen J; Kumar Pole A; Belrhali H; Ribas de Pouplana L; Sharma V; Sharma A
    Acta Crystallogr D Biol Crystallogr; 2013 May; 69(Pt 5):785-95. PubMed ID: 23633587
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo.
    Novoa EM; Camacho N; Tor A; Wilkinson B; Moss S; Marín-García P; Azcárate IG; Bautista JM; Mirando AC; Francklyn CS; Varon S; Royo M; Cortés A; Ribas de Pouplana L
    Proc Natl Acad Sci U S A; 2014 Dec; 111(51):E5508-17. PubMed ID: 25489076
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy.
    Xie SC; Metcalfe RD; Dunn E; Morton CJ; Huang SC; Puhalovich T; Du Y; Wittlin S; Nie S; Luth MR; Ma L; Kim MS; Pasaje CFA; Kumpornsin K; Giannangelo C; Houghton FJ; Churchyard A; Famodimu MT; Barry DC; Gillett DL; Dey S; Kosasih CC; Newman W; Niles JC; Lee MCS; Baum J; Ottilie S; Winzeler EA; Creek DJ; Williamson N; Parker MW; Brand S; Langston SP; Dick LR; Griffin MDW; Gould AE; Tilley L
    Science; 2022 Jun; 376(6597):1074-1079. PubMed ID: 35653481
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assembly of the novel five-component apicomplexan multi-aminoacyl-tRNA synthetase complex is driven by the hybrid scaffold protein Tg-p43.
    van Rooyen JM; Murat JB; Hammoudi PM; Kieffer-Jaquinod S; Coute Y; Sharma A; Pelloux H; Belrhali H; Hakimi MA
    PLoS One; 2014; 9(2):e89487. PubMed ID: 24586818
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure-guided conversion from an anaplastic lymphoma kinase inhibitor into Plasmodium lysyl-tRNA synthetase selective inhibitors.
    Zhou J; Xia M; Huang Z; Qiao H; Yang G; Qian Y; Li P; Zhang Z; Gao X; Jiang L; Wang J; Li W; Fang P
    Commun Biol; 2024 Jun; 7(1):742. PubMed ID: 38890421
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis of febrifugine derivatives and development of an effective and safe tetrahydroquinazoline-type antimalarial.
    Kikuchi H; Horoiwa S; Kasahara R; Hariguchi N; Matsumoto M; Oshima Y
    Eur J Med Chem; 2014 Apr; 76():10-9. PubMed ID: 24565569
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
    Dali B; Keita M; Megnassan E; Frecer V; Miertus S
    Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structure-Guided Design of Halofuginone Derivatives as ATP-Aided Inhibitors Against Bacterial Prolyl-tRNA Synthetase.
    Cheng B; Cai Z; Luo Z; Luo S; Luo Z; Cheng Y; Yu Y; Guo J; Ju Y; Gu Q; Xu J; Jiang X; Li G; Zhou H
    J Med Chem; 2022 Dec; 65(23):15840-15855. PubMed ID: 36394909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Halofuginone - the multifaceted molecule.
    Pines M; Spector I
    Molecules; 2015 Jan; 20(1):573-94. PubMed ID: 25569515
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of Plasmodium falciparum phenylalanine tRNA synthetase provides opportunity for antimalarial drug development.
    Sharma M; Mutharasappan N; Manickam Y; Harlos K; Melillo B; Comer E; Tabassum H; Parvez S; Schreiber SL; Sharma A
    Structure; 2022 Jul; 30(7):962-972.e3. PubMed ID: 35460612
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recent advances in the biology and drug targeting of malaria parasite aminoacyl-tRNA synthetases.
    Khan S
    Malar J; 2016 Apr; 15():203. PubMed ID: 27068331
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Computational insights into the suicide inhibition of Plasmodium falciparum Fk506-binding protein 35.
    MacDonald CA; Boyd RJ
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3221-5. PubMed ID: 26091727
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis, characterization and in vitro evaluation of novel enantiomerically-pure sulphonamide antimalarials.
    Anusha S; Sinha A; Babu Rajeev CP; Chu TT; Mathai J; Ximei H; Fuchs JE; Shivananju N; Bender A; Preiser PR; Rangappa KS; Basappa ; Chandramohanadas R
    Org Biomol Chem; 2015 Nov; 13(43):10681-90. PubMed ID: 26347024
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery and pharmacological characterization of a new class of prolyl-tRNA synthetase inhibitor for anti-fibrosis therapy.
    Shibata A; Kuno M; Adachi R; Sato Y; Hattori H; Matsuda A; Okuzono Y; Igaki K; Tominari Y; Takagi T; Yabuki M; Okaniwa M
    PLoS One; 2017; 12(10):e0186587. PubMed ID: 29065190
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A new mechanism of post-transfer editing by aminoacyl-tRNA synthetases: catalysis of hydrolytic reaction by bacterial-type prolyl-tRNA synthetase.
    Boyarshin KS; Priss AE; Rayevskiy AV; Ilchenko MM; Dubey IY; Kriklivyi IA; Yaremchuk AD; Tukalo MA
    J Biomol Struct Dyn; 2017 Feb; 35(3):669-682. PubMed ID: 26886480
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials.
    Skinner-Adams TS; Stack CM; Trenholme KR; Brown CL; Grembecka J; Lowther J; Mucha A; Drag M; Kafarski P; McGowan S; Whisstock JC; Gardiner DL; Dalton JP
    Trends Biochem Sci; 2010 Jan; 35(1):53-61. PubMed ID: 19796954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.